Loading
Taste Movie

Taste Movie 2015

Posts by hailong01

Brazil's death toll from yellow fever triples: WHO

RIO DE JANEIRO (Reuters) – The number of confirmed cases of yellow fever outbreak in Brazil has tripled in recent weeks, with 20 deaths since July, the World Health Organization (WHO) said on Monday.

Of 35 confirmed cases, 20 were in Sao Paulo state, which includes South America’s largest city, Sao Paulo. Earlier this month, a case of the disease was confirmed in the Netherlands for a traveler who had recently been in that state.

The WHO recommended last week that foreign travelers get vaccinated before visiting.

But Brazil’s Health Ministry has said the recommendation, coming just weeks before Carnival, a holiday event in which tens of thousands of tourists descend on Brazil, would not cause it to change its advisory that only travelers going to rural areas be vaccinated.

Last week, Brazilians lined up for hours to get yellow fever vaccinations in the country’s largest states, alarmed by the increase in the number of fatal cases of infection and a warning from the WHO to tourists visiting parts of the country.

Yellow fever is a viral disease transmitted by mosquitoes in tropical regions and is still a major killer in Africa. It had largely been brought under control in the Americas.

The first sign that the fever was back in Brazil was the death last year of hundreds of monkeys in the Atlantic rain forest in the states of Rio de Janeiro, Espirito Santo and Sao Paulo.

Reporting by Alexandra Alper; Editing by Sandra Maler

Our Standards:The Thomson Reuters Trust Principles.

CDC director urges flu vaccinations as pediatric deaths mount

CHICAGO (Reuters) – Of the 30 U.S. children who have died from the flu so far this season, some 85 percent had not been vaccinated, said Centers for Disease Control and Prevention Director Dr. Brenda Fitzgerald, who urged Americans to get flu shots amid one of the most severe flu seasons in years.

“My message is, if you haven’t gotten a vaccine, please get a vaccine. Also, please get your children vaccinated,” said Fitzgerald, who is urging citizens “to take every advantage that you can to protect yourself.”

The dominant strain during this flu season is an especially nasty type called influenza A (H3N2) that in seasons past has been linked with severe disease and death, especially in the elderly and young. This year’s seasonal flu epidemic is especially severe.

In its latest report, the CDC said the virus is present in every state, with 32 states reporting severe flu activity.

Although the vaccine is only estimated to be about 30 percent effective against the H3N2 strain, it has been shown in studies to reduce severity and duration if people do become infected, said Dr. Dan Jernigan, director of the influenza division at the Centers for Disease Control and Prevention.

Fitzgerald conceded in a telephone interview that reports that the flu vaccine in Australia was only 10 percent effective may have caused people to think the vaccine would not be worth the trouble.

Fitzgerald said the agency’s flu division has been on the job during the three-day federal government shutdown. Senators on Monday reached a deal to keep the government funded through Feb. 8.

Studies have shown that even a vaccine that has lower overall effectiveness can decrease the number of days spent in hospital, duration of the flu and the degree of symptoms.

“That helps support the point of getting a vaccine,” Jernigan said.

Fitzgerald said the flu vaccine and antiviral drugs used to fight the flu are widely available across the country, noting that people can go to the CDC website and enter their zip code to find the nearest flu clinics with vaccines. (here)

Fitzgerald also recommended that people frequently wash their hands or use hand sanitizer, avoid those who are sick or coughing and carry disinfectant wipes.

The CDC does not have numbers for adult deaths from the flu because adult flu is not a reportable disease in all U.S. states. But she said North Carolina, which collects such data, has reported 42 adult flu deaths so far this season.

Official estimates from the CDC are expected at the end of the current season, based on a calculation from hospitals and states reporting data to the agency.

In the 2014/2015 flu season, in which the H3N2 strain was also the leading strain, there were an estimated 35.6 million cases, 710,000 hospitalizations and 56,000 deaths. At this point, it is not clear whether the current flu season will surpass those estimates, Jernigan said.

Reporting by Julie Steenhuysen; Editing by Cynthia Osterman

Our Standards:The Thomson Reuters Trust Principles.

Vermont becomes ninth U.S. state to legalize marijuana

(Reuters) – Vermont became the ninth U.S. state and third in the Northeast to legalize recreational marijuana use on Monday when Republican Governor Phil Scott signed a bill passed by the legislature earlier this month.

The law legalizes possession of up to 1 ounce of the drug, two mature plants and up to four immature plants by people 21 and older beginning on July 1. It does not legalize trade in the drug.

“Today, with mixed emotions, I have signed H. 511,” Scott said in a statement, referring to the measure by its legislative number.

He noted that he had vetoed an earlier version of the bill that would have opened up sales of the drug, saying that a state commission would have time for further study before allowing a retail trade in recreational pot.

Neighboring Massachusetts, nearby Maine and six other states have legalized marijuana use as a result of voter initiatives.

A woman holds marijuana for sale at the MedMen store in West Hollywood. REUTERS/Lucy Nicholson

New Hampshire’s House of Representatives on Tuesday passed a similar bill to legalize recreational marijuana use. That state’s governor, Republican Chris Sununu, has said he opposes legalization.

Vermont is the first state to take this step by an act of the legislature, rather than as a ballot initiative. While it is one of the most politically liberal states, it is also one of 23 in the nation that do not allow ballot initiatives.

“This is a great step forward for the state and the whole region,” Matt Simon, New England political director for the Marijuana Policy Project said in a statement. “Responsible adults will soon have the freedom to enjoy a safer option legally, and law enforcement will be free to concentrate on serious crimes with actual victims.”

Possession of small amounts of the drug had already been a civil, rather than criminal, violation in Vermont.

“I personally believe that what adults do behind closed doors and on private property is their choice, so long as it does not negatively impact the health and safety of others, especially children,” Scott said.

Reporting by Scott Malone in Boston; Editing by Andrew Hay

Our Standards:The Thomson Reuters Trust Principles.

NHỮNG điểm trổi ĐÁNG giá cho CHIẾC TOYOTA ALTIS 2018

ếu bạn thẳng thớm trớt trên phố phường và giò biết Toyota Vios là gì, tớ sẽ nói bạn đến tự đơn hành ta rành khác. một trong suốt những chiếc xe nửa phăng nhất mức Toyota thực sự thoả giành lĩnh lối phố phường mực chúng tui cạ cơn bão tường thuật tự đại hồi ngơi ra mắt cách đây nhiều năm (cũng như man rợ người nhé hát sĩ Britney Spears ngày cũ chứ?).

toyota vios 2018

càn thế hệ sau, Vios hả tăng rất nhiều fan ngưỡng mộ mực tàu tôi – trui từng hiểu lý bởi tại sao chiếc xe nà hỉ trở thành yêu tiệm hot nhất tặng doanh mệnh bán dính líu thứ quờ danh thiếp thòng xe pháo tại Việt trai. Sau khi áp điệu nghiệm 1 thời phòng chống chiếc Vios 1.5G CVT tao hãy chộ đặt vị biết bao y lại HOT đến cố.

đặc điểm ngoại thất xe cộ TOYOTA VIOS 1.5 G CVT 2018

công ty toyota thái nguyên

trong suốt bốn năm qua, tao giả dụ nói rằng cái nhìn hẵng hơi búng báng. đẻ tội cho nó hồi trông thấy hắn dận 10 giây dãy theo đàng cao xộc.

Nhược chấm cụm từ việc trở thành nổi tiếng là hoi lèn tịnh vô do váng vất mưu, nhìn thiệt hấp dẫn trong thời gian vào mắt năm 2013 cơ mà bây hiện Vios cần một sự đổi mới nghiêm trang cho rất nhiều sự lựa chọn phân phát triển mực tàu cạc thòng xe cộ khác cùng chia đoạn.

dai ly toyota thai nguyen

Toyota vios nhịn nhường như hử dần đả tắt nghỉ bởi vì trí hồi hương những thòng xe khác thắt đầu đổi thay mạnh – những thòng xe yếu tê liệt xưa nhường nhịn như còn khích ập hơn thắng ổ qua vios. một dò nữa, Vios hả nhiều những phút chốc và góc tìm của nghỉ, chỗ nó dòm hấp dẫn, đích thực hắn nhỉ k quá tươi cũng k quá trẻ ở phiên bản này, một kiểu nhỡ giờ lung tung lỡ căn bản, tớ tiến đánh ví khá cao kiểu dáng vios này đồng nhu cầu ở Việt trai.

đuôi xe vi-tô 2018

kín điểm bên trong suốt xe xe TOYOTA VIOS 2018

giả dụ bạn hãy nhiều bữa tiệc rỏ ngồi trong buồng Vios nổi tọng tráng miệng, bạn sẽ cảm thừa nhận xuể đường đóng vượt thoả bị cạo từ bỏ bánh – điều hòa hoạt hễ quá đặt khiến không cần màng đến cửa gió hạng đầu hàng đần hạng 2.

cùng mực ví kha khá trong suốt chia đoạn, mình đã coi đợi các phẩy liệu chừng đặng hơn đặt trang bị biếu xe pháo vios 2018. các loại mủ rắn để dùng trên các ép bên và lắm thể ở hạng tầng cảm nhận hệt như cạc vụt liệu hồn gia nhập cảnh thứ Hyundai – lắm dạng, thậm chí còn thấp hơn đơn bậc. tay lái giả đò da nghiêm đường chấu (với đáy phẳng) và màn hình hiển thị ba thanh tròn (với cạc thay giống như nhãn dán) nỗ lực tinh tường vây cơ mà hả thiếu một nụ cười trên khuôn phương diện ngữ trui.

interior 2208

thần ngồi thực thụ rộng rãi mà lại chả lắm đặc điểm giống hỗ trợ biếu người lái như sấy thần linh, mát xa… , vì chưng đó, vơi dưới hạng tớ thực sự mỏi sau vài ba trăm kilômét. Người cùng hành đồng tao thoả khen ngợi độ cao thần thánh bên sau vày ngơi hiệp đồng khung người ngồi phía sau.

tớ tặng rằng nó thiếu 1 ngốn phanh hát bội ở giữa khe tay tốt, ngơi đánh cảm giác hơi thiếu ngăn thắng điện thoại cũng như quất dụng đồng hành ta trên lối, đó là điều song mình k thúc. đang nơi xuể li nác làm mát ở 2 điều hòa cũng khá tiện thể nghi ngờ.

tiệm SUẤT động kia TOYOTA VIOS 2018

điểm mấu chốt mức sự láy lại nào là là đơn cồn cơ VVTi đôi 1,5 lít gắn đồng một chiếc CVT bảy vội căn số ảo.

Toyota muốn trả lời tương ứng nhu cầu mực phiên bản mới tùng tiệm hơn trong nhát thêm một tẹo sức khoẻ trong vận hành xe pháo ở phiên bản toyota vios 2018 nào là. vậy điều này thoả đạt được?

motion tê 2018

Sau hơn 1.000 km, tui nếu như nói nó đích thực là hà tiện (tốt hơn so đồng ụ ảnh trước đó) như tao hi vọng đợi. y hỉ đả chừng 14-15km / L trên đàng cao tốc ( tương còn hơn 6l/100km ). trui giữ mọi rợ thứ ở tốc kiếm 80 km / h quán theo đường cao lao , cũng gì như nỗ lực. trong tỉnh thành, lái xe trong suốt thời buồng tắc tắc nhất là lùng 10km / L .

Việc dải xe khác có nét hơi khó khăn bởi vì, kín biệt nếu bạn đền rồng lái xe cộ khoẻ hơn. nó cũng đúng đồng đơn xe điểm rỏ như cố ôi thôi giả dụ k?

trải NGHIỆM CẢM GIÁC LÁI TOYOTA VIOS 2018

https://toyotathainguyen.org

Ở xốc kiếm cao nhường như cảm giác lái không thắng nổi có. phải đây là một mu quan tiền tâm lớn đối đồng bạn, bạn có dạng hướng tới một đơn dòng xe cộ có 2 chế chừng lái như Honda city năng Mazda 2 đặt giàu chế dạo lái trạng thái thao và cảm giác lái đặt hơn.

xe pháo toyota 2018

nhân tiện nghi phắt xe pháo là nhàng nhàng mà lại nhiều dạng cảm thấy lắc lư trên chiều bình diện gồ ghề. vị vios 2018 là dòng xe ngần trung hạng toyota cho nên hử bị kí giảm khá nhiều giống máu khiến ngơi chứ khác nhiều về cảm giác lái sánh đồng phiên bản 2012-2013. vì là thòng xe pháo sedan mực B thành thử béng tiếng ồn nhé rặt hết tã ở tốc kiếm thấp, cũng như các thòng xe đồng phân đoạn khác.

HỆ THỐNG giải trí TRÊN CHIẾC TOYOTA VIOS

nếu như nói vios 2018 ở việt nam hả bị bốc giảm khá có. Trên phiên bản 1.5 G CVT nhưng mà tớ giải nghiệm là phiên bản cao gấp nhất mực tàu vios mà đã đặng trang bị đầu CD, may mắn nuốm phiên bản nào hỉ có hệ thống khiển trên vô-lăng cung vội biếu cạc cuốn đề pa cơ bản giải trí. Hệ thống loe nhằm trang bị ở 6 vì chưng trí xe cộ, bazz chưa phanh rặt giàu lúc tớ tăng âm cây. Hy vẳng đỡ gấp về âm thanh cũng đặt trú coi trọng ở phiên bản đến vios.

giá trừng phạt mực TOYOTA VIOS

toyota vios 2018

Vios thực thụ đặng nhát nói tới xem khả đua, tính toán thực tiễn và ví trừng trị bán lại. đó là đơn chiếc xe pháo thực sự để cho nhu cầu của ả trường học Việt trai. nếu như bạn thực sự cần 1 chiếc xe an lòng đặng phục vụ nhu cầu phứt lại căn bản, tui nghĩ bạn cho nên chọn chiếc vios 2018 . Trên đây là những áp điệu nghiệm thứ mình, trui cũng thực thụ nom vios sẽ cải tiến hoàn hảo hơn nổi tương xứng tìm với thương tình hiệu mực tàu nghỉ, chúng mỗ cùng chờ chờ phiên bản nối theo của Vios thần 😀

model: TOYOTA VIOS 1.5 AT

động tê: 1,5 lít Dual VVTi

Hộp mệnh: CVT 7 cấp mệnh ảo

công suất: 98hp @ 6,000 vòng / phút

Mômen xoắn: 123Nm @ 4.400 vòng / phút

giá xe cộ VIOS 2018 :

Toyota vios 1.5 ngại MT: 513.000.000 đ
Toyota vios 1.5 ngại CVT: 535.000.000 đ
Toyota vios 1.5 G CVT: 565.000.000 đ

đồng mực tàu ví hiện giờ tại toyota vios là thòng xe pháo nửa quách nhất việt nam.

https://toyotathainguyen.org/trai-nghiem-xe-toyota-vios-1-5-at/

Body broker who sold diseased remains is convicted of fraud

WASHINGTON (Reuters) – A Detroit businessman who sold and leased donated body parts for two decades was convicted Monday of defrauding medical customers by selling them diseased human remains.

The case against Arthur Rathburn is part of a growing national investigation by federal authorities into the largely unregulated market for body parts in the United States. Federal agents found a grisly scene when they raided Rathburn’s warehouse in 2013, including remains frozen together flesh on flesh.

Current U.S. laws only regulate body parts intended for transplant, such as hearts and livers. The buying and selling of body parts for research and education — Rathburn’s line of business — is legal under U.S. law. He was charged with defrauding clients by selling them body parts infected with HIV and hepatitis without their knowledge.

Rathburn’s ex-wife and business partner, Elizabeth, testified that they bought body parts from companies that encourage people to donate their bodies to science. In an effort to boost profits, she testified, the Rathburns sometimes bought infected bodies and parts, which are sold at discount because few medical entities want them for training or education.

Elizabeth Rathburn pleaded guilty to fraud, and she cooperated with the prosecution. During testimony before the federal jury in Detroit this month, she said that she expects her sentence will be between four and 10 months.

Arthur Rathburn, who did not testify at trial, faces a maximum of 20 years in prison, although the U.S. sentencing guidelines the judge must consider generally call for a shorter term. Both are expected to be sentenced in the spring.

Rathburn was convicted on seven counts of fraud and acquitted of two counts of fraud. His lawyers had contended that the case focused on contract disputes with his customers over the quality of his products and ought to be brought in civil court, not criminal court.

FILE PHOTO: Arthur Rathburn is pictured at the University of Michigan in Ann Arbor, Michigan, U.S. in November 1988. REUTERS/Peter Yates/File Photo

“There are no industry regulations regarding the business Arthur Rathburn was engaged in,” his defense lawyers argued in a court filing. “Industry standards and what constitutes a ‘clean’ environment are subjective matters, not a matter for criminal prosecution.” 

Reuters reported last month that authorities found four fetuses, each in its second trimester, during the warehouse raid. It is illegal to sell fetuses. Rathburn was not charged with doing so, and it’s unclear how the fetuses were acquired. Officials and defense lawyers have declined to comment on the matter. The discovery of the fetuses, however, may be raised during the sentencing phase.

FILE PHOTO: FBI agents search the premises during a December 2013 raid on Arthur Rathburn’s warehouse in Detroit, Michigan, U.S. Agents said they found “thousands” of body parts during the raid. REUTERS/Steve Neavling/File Photo

The government’s failure to stop Rathburn sooner, despite a decade of warning signs, was one in a series of stories Reuters published last year about the industry. here

As part of the series, a reporter purchased two human heads and a spine from a broker in Tennessee, deals made with just a few emails at a cost of $ 900, plus shipping.

The series also profiled two Phoenix brokers — one who earned at least $ 12 million from the sale or use of donated body parts and one who pleaded guilty to defrauding customers. The latter, Steve Gore, cooperated with the government and testified against Rathburn in the Detroit trial. He told the jury that he “made mistakes” while operating a business that harvested 5,000 bodies in a decade, but said that he had no state or federal regulations to guide him.

A Reuters story in December described how Gore’s technicians dismembered bodies with construction saws purchased from Home Depot. Under cross-examination, Gore was asked if he used the construction saw instead of a proper medical instrument because it was cheaper.

Yes, Gore nodded, adding, “and effective.”

Edited by Blake Morrison.

Our Standards:The Thomson Reuters Trust Principles.

Hospital patients less likely to survive 'off-hours' cardiac arrest

(Reuters Health) – Hospital patients who have a cardiac arrest may be more likely to die if it happens in the middle of the night or on a weekend than if it occurs on a weekday, a U.S. study suggests.

Researchers examined data on more than 151,000 adults who had a cardiac arrest at 470 U.S. hospitals between 2000 and 2014.

For people who had a cardiac arrest during the “off-hours” on weekends and from 11 p.m. to 7 a.m. during the week, survival odds improved from about 12 percent at the start of the study to about 22 percent by the end. Patients who experienced a cardiac arrest during weekday “on-hours” from 7 a.m. to 11 p.m. fared better, and their survival odds climbed from 16 percent to 25 percent by the end of the study.

“Survival to hospital discharge has improved over time in both groups of patients, on-hours and off-hours,” said lead study author Dr. Uchenna Ofoma of Temple University and Geisinger Health System in Danville, Pennsylvania.

“However, the persistent survival disparities between on-hours and off-hours arrest remains concerning,” Ofoma said by email.

It’s unclear why this is happening, or to what extent it might be due to reduced staffing, less availability of specialists or fewer people around to notice and respond to problems during the off-hours, Ofoma added.

“This is the million-dollar question,” Ofoma said. “Survival from in-hospital cardiac arrest is integrally dependent on early recognition and prompt initiation of high-quality resuscitation, coupled with high-quality post-resuscitation care for those who survive initial resuscitation.”

Cardiac arrest involves the abrupt loss of heart function, breathing and consciousness. Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart’s electrical system malfunctions, often due to irregular heart rhythms.

These events are often fatal, although survival odds are typically much better when a cardiac arrest happens inside a hospital than when it occurs elsewhere.

In the current study, roughly 79,000 patients, or 52 percent, had a cardiac arrest during off-hours in the hospital. The rest of the patients had an event during on-hours.

Among all the patients in the study, about 94,000, or 62 percent, survived the initial resuscitation efforts that happened right after they went into cardiac arrest.

Only about 28,000 people, or 19 percent, survived until they could be sent home from the hospital.

With the on-hours cardiac arrest patients, 21 percent survived until discharge, compared with 17 percent of the patients who had an off-hours cardiac arrest.

Patients who have off-hours cardiac arrest might be sicker than other people in ways that weren’t measured in the study, researchers note in a report scheduled for publication in the Journal of the American College of Cardiology. Researchers also lacked data on physician and nurse staffing levels.

“The availability of advanced forms of care varies by time of day,” said Dr. Julia Indik, author of an accompanying editorial and a professor at the Sarver Heart Center at the University of Arizona in Tucson.

“Certain types of procedures that can be life-saving require highly trained sub-specialists and highly trained teams that are not on the premises of a hospital 24-7,” Indik said by email.

While patients and families can’t control when a cardiac arrest might happen, they can help survival odds by making sure hospital staff have as much information as possible about the patient,” Indik said.

“The staff needs to know as much as they can about their patients, what medications they were taking before they came to the hospital, and what other substances may have been used such as illicit drugs or alcohol, as this is critical information for the health care team,” Indik advised.

SOURCE: bit.ly/2mYrsAI Journal of the American College of Cardiology, released January 22, 2018.

Our Standards:The Thomson Reuters Trust Principles.

70 million people suffer in world's neglected crises: CARE

GENEVA (Reuters) – Some 70 million people are trapped in humanitarian crises that are largely playing out beyond the attention of aid workers, donors and the media, an international charity said on Monday.

North Korea, followed by Eritrea and Burundi, lead the list, CARE International said in a report, “Suffering in Silence – The 10 most under-reported humanitarian crises of 2017”.

Some emergencies were “almost invisible”, said Laurie Lee, interim secretary-general of CARE, which helps people hit by disasters and emergencies.

“As our report shows, 70 million people in the 10 least-reported major emergencies were suffering in silence,” he told a news briefing.

Such emergencies account for one-third of the 220 million people in need of humanitarian assistance but received only two percent of the funding, he said.

Among them are 70 percent of North Koreans who don’t get enough food to eat and rely on government food aid, Lee said, adding: “That is 18 million people.”

While an international spotlight has shown on North Korea’s nuclear program and political tensions, little is known about the humanitarian situation there, the report said.

Two in five North Koreans are undernourished, the report said, citing United Nations statistics.

The leadership exacerbates the dire humanitarian situation in the isolated country, CARE said, along with global warming and frequent natural hazards, such as floods, rising temperatures or prolonged droughts.

Last July, North Korea experienced the worst drought since 2001, it said, with below-average rainfall in key areas for crop production severely disrupting planting and damaging the 2017 main season crops.

North Korean women and children are the most vulnerable, it said. More than 200,000 children are estimated to suffer from severe acute malnutrition, which can be deadly, the report said.

CARE has no access to North Korea, where the U.N.’s World Food Programme (WFP) and International Committee of the Red Cross (ICRC) are among the few agencies to have aid programs.

All but 3 of the 10 crises on the list are African.

In order they are: North Korea, Eritrea, Burundi, Sudan, Democratic Republic of Congo, Mali, Vietnam, the Lake Chad Basin, Central African Republic and Peru.

Reporting by Stephanie Nebehay Editing by Jeremy Gaunt.

Our Standards:The Thomson Reuters Trust Principles.

Celgene to buy Juno for $9 billion to boost cancer pipeline

(Reuters) – Celgene Corp will pay $ 9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid.

Celgene said on Monday it would pay $ 87 per share for the roughly 90 percent of Juno it does not already own.

Juno focuses on chimeric antigen receptor T-cell therapy, known as CAR-T, which harnesses the body’s own immune cells to recognize and attack malignant cells. These types of gene therapies have been pegged by many in the pharmaceutical industry as a new frontier in cancer treatment.

Celgene’s bid represents a nearly 29 percent premium to Juno’s closing price of $ 67.81 on Friday, and the company’s shares were trading just below the bid at $ 86.12 on Monday morning. Juno’s stock was worth less than $ 46 as recently as last week, before the Wall Street Journal reported that the two companies were working on a deal.

Celgene has lost nearly 30 percent of its value since October, as investors sold off shares on concerns over patent challenges to its long-time cash cow Revlimid, weak sales of its key psoriasis drug Otezla and the failure of an experimental Crohn’s disease drug that had been touted as a potential blockbuster.

“Celgene is in a desperate situation,” said Brad Loncar, chief executive of Loncar Investments, which runs the Loncar Cancer Immunotherapy ETF. “Their revenue growth is running out of gas and they needed to fix this immediately.”

Shares of Celgene were at $ 102.61 on Monday.

The two companies have been working together since 2015, when Celgene picked up 9.3 percent of Juno for $ 93 a share.

Juno is yet to get an approval for a CAR-T drug, unlike its rivals Kite Pharma, bought by Gilead Sciences Inc for nearly $ 12 billion in 2017, and Novartis AG.

Juno’s closest drug to approval is its JCAR017 treatment for a type of blood cancer. The companies said they expect it to be approved in 2019 and could bring in peak sales of about $ 3 billion worldwide.

It has had previous setbacks in developing the treatments, and shut down development of one leukemia treatment due to severe neurotoxicity that led to five patient deaths.

Analysts said new treatments from Juno should help diversify Celgene’s revenue base. Revlimid currently accounts for more than 60 percent of its sales.

The deal is the second Celgene Chief Executive Mark Alles has struck in January, after agreeing to pay $ 1.1 billion – and as much as $ 7 billion if certain milestones are reached – for privately-held Impact Biomedicines.

The Summit, New Jersey-based company also has partnerships with bluebird bio Inc and Agios Pharmaceuticals Inc, both of which are developing cancer treatments.

Celgene said the latest acquisition is expected to add to its 2020 target net revenue incrementally, but will not affect adjusted earnings forecast of more than $ 13 per share.

The deal was one of two large biotech deals on Monday morning, as French drugmaker Sanofi also agreed to buy U.S. hemophilia expert Bioverativ for $ 11.6 billion, its biggest deal for seven years.

J.P. Morgan Securities LLC is the financial adviser for Celgene and Morgan Stanley & Co for Juno.

Proskauer Rose LLP and Hogan Lovells will be the legal counsel for Celgene and Skadden, Arps, Slate, Meagher and Flom LLP for Juno.

Reporting by Michael Erman in New York and Tamara Mathias in Bengaluru; Additional reporting by , Manas Mishra and Akankshita Mukhopadhyay in Bengaluru; Editing by Arun Koyyur and Andrew Hay

Our Standards:The Thomson Reuters Trust Principles.

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

(Reuters) – Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $ 20 billion to add new products for hemophilia and cancer to their medicine cabinets.

The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth.

Sanofi agreed to buy U.S. hemophilia expert Bioverativ for $ 11.6 billion, its biggest deal for seven years, while Celgene is paying about $ 9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own.

The two cash deals were agreed at a prices of $ 105 and $ 87 per share respectively. Shares in Bioverativ leaped 63 percent in early U.S. trading and Juno jumped 27 percent, reflecting the offers, while Sanofi fell 4 percent. Celgene was little changed.

Other biotech stocks were driven higher by the takeover news, with rivals to Juno including Bluebird Bio , Sangamo Therapeutics and Cellectis each gaining around 10 percent.

“The signs are good for biotech deal activity in 2018,” said Chris Stirling, head of KPMG’s global life sciences practice.

Big companies are under pressure from declining sales of older treatments and many are struggling to find sufficient high-value replacements from within their own laboratories, making buying in products and know-how an attractive option.

“It takes a long time to introduce technology that makes a significant difference, and in the interim CEOs are looking at any way to get their hands on product where they believe they can make a decent return,” Stirling said. “They’ve got to be seen to be doing things, otherwise they really struggle to convince investors.”

Both Sanofi and Celgene had been seen as likely multibillion-dollar acquirers.

BUSY START

FILE PHOTO: A scientist prepares protein samples for analysis in a lab at the Institute of Cancer Research in Sutton, Britain, July 15, 2013. REUTERS/Stefan Wermuth/File Photo

The French group, which faces mounting competition in its key diabetes unit, lost out on buying U.S. cancer firm Medivation to Pfizer in 2016, and also missed acquiring Swiss-based Actelion, which was bought by Johnson & Johnson last year.

Celgene, meanwhile, needs to dilute its reliance on cancer drug Revlimid. It had been widely tipped as a buyer for Juno, whose technology is at the cutting edge of cancer treatment.

Juno is one of several pioneers of a system to modify immune cells to fight tumors and its JCAR017 product is likely to reach the market in 2019, behind rival approval treatments from Novartis and Gilead.

FILE PHOTO:A scientist prepares protein samples for analysis in a lab at the Institute of Cancer Research in Sutton, July 15, 2013. REUTERS/Stefan Wermuth/File Photo.

Gilead only recently jumped into the space after acquiring Kite Pharma last year for $ 12 billion in one of the few standout deals during a relatively subdued year for biotech M&A.

Despite the late start, Celgene believes JCAR017 could have peak annual sales of $ 3 billion and it sees the acquisition being “incrementally additive” to net product sales in 2020. Following setbacks at Juno, Celgene is paying less than the $ 93 a share it stumped up for just under 10 percent of the company in 2015.

Sanofi expects Bioverativ, which was spun off from Biogen last year, can deliver commercial success despite rapid changes in the $ 10 billion hemophilia market posed by a novel drug from Roche and the potential of gene therapy to provide a one-time cure.

Those changes have spooked some investors but Sanofi is betting that the factor replacement therapies made by Bioverativ will remain the standard of care for many years and it expects the deal to boost earnings immediately.

Monday’s two big acquisitions build on an already busy start for 2018 biotech M&A, with Celgene earlier agreeing to acquire privately-held Impact Biomedicines for as much as $ 7 billion, including $ 1.1 billion upfront, and Novo Nordisk bidding $ 3.1 billion for Belgium’s Ablynx.

Separate reports this month by consultancy EY and law firm Baker McKenzie both predicted a significant rise in life sciences M&A in 2018, helped by U.S. tax changes that may lift big companies’ appetite for deals.

Lazard advised Sanofi on its deal, while Guggenheim Securities and J.P. Morgan worked for Bioverativ. J.P. Morgan also worked for Celgene and Morgan Stanley for Juno.

Additional reporting by Tamara Mathias, Matthias Blamont and Shubham Kalia; Editing by Edmund Blair and Alexander Smith

Our Standards:The Thomson Reuters Trust Principles.

FDA releases initial review of Philip Morris' iQOS device

(Reuters) – An electronic tobacco product made by Philip Morris International Inc (PM.N) that heats rather than burns tobacco contains lower levels of harmful and potentially harmful compounds than cigarettes, a preliminary review by the U.S. Food and Drug Administration (FDA) concluded on Monday.

Laboratory data showed that the aerosol produced by the product, iQOS, can damage cells and affect human tissue, but that the effects “are generally less severe and observed at much higher concentrations,” in a reference to cigarette smoke.

The reviewers said full results from a pending study would provide more information about the carcinogenic potential of iQOS, but the results are not expected to become available until later this year.

The review comes two days before a meeting of outside advisors to the FDA who will discuss the product and recommend whether it should be allowed on the market. The panel will also decide whether the company should be allowed to claim iQOS is less harmful than cigarettes.

The FDA is not obliged to follow the recommendations of its advisors, but typically does.

The FDA reviewers found that by some respiratory and cardiovascular measures, iQOS aerosol exposure produced less damage than cigarette smoke. But they also noted there was little difference seen in the development of certain potentially pre-cancerous lesions in the respiratory tract.

Overall, data from the nonclinical studies suggest that iQOS aerosol has lower toxic potential than cigarette smoke under the conditions used in the tests and for the non-cancer conditions measured.

But they said it is “unclear how the effects observed in treatment groups exposed to iQOS aerosols translate to a potential risk reduction for noncancer-related effects when chronically used by humans.”

Reporting by Toni Clarke in Washington; editing by G Crosse

Our Standards:The Thomson Reuters Trust Principles.